ICORG office is lighting up blue this month to show our support for Blue September. Blue September is part of an international campaign to raise awareness for male related cancers in Ireland. Blue September seeks to tackle the fact that men are more likely to develop and die of cancer than women and that men are less […]
MTCI Foundation and its partners are delighted to announce the inauguration of the National Cancer Research Centre of Ireland (NCRCI).
ICORG’s 4th NEJM Publication is now available and it’s exciting news for some Lung Cancer patients.
ICORG has 2 first author papers published in leading journals this month – Journal of Clinical Oncology & Annals of Oncology.
Prof John Crown will chair a meeting in the Herbert Park hotel tomorrow, Friday 14th of June, to discuss the feasibility a “virtual” National Cancer Research Centre of Ireland.
The event is hosted by Molecular Therapeutics for Cancer Ireland (MTCI) and includes international experts, Sir Philip Cohen from Dundee, Prof Ulrik Ringborg from Sweden and Dr Mel Sorensen from the US, who will provide insight into international models for cancer research centres.
The ANGIOPREDICT prospective translational study is an Exploratory Phase II clinical trial comprising biomarker analysis of oxaliplatin plus fluorouracil/leucovorin (FOLFOX) in combination with bevacizumab (bvz) in first line treatment of metastatic colorectal cancer (CRC) expressing mutant K-ras – AC-ANGIOPREDICT’.
Integrative methods for prostate cancer research: bridging molecular and population science on 14 June 2013.
This one-day course will provide in-depth exposure to fundamentals of epidemiology and molecular pathology of prostate cancer.
Each year the International Clinical Trials Day is celebrated around the world on or near the 20th of May to celebrate the day that James Lind began his controlled trial comparing the different treatments for scurvy on the 20th May 1747.
8th May 2013 is the first World Ovarian Cancer Day. Ovarian cancer has the lowest survival rate of all gynecologic cancers, and is characterized around the world by a lack of awareness of symptoms and late stage diagnosis.